Preventing Alzheimer’s Disease and Dementia in 2026: An Evidence-Based Review of Lifestyle, Supplements, Biomarkers, and Metabolic Health
Updated: August 2026 | Article type: Evidence review | Original publication: 2022; substantially revised and rebuilt in 2026 Clinical focus: Alzheimer’s disease prevention, dementia risk reduction, multidomain lifestyle intervention, p-tau217 blood biomarkers, metabolic health, GLP-1 receptor agonists, SGLT2 inhibitors, and dietary supplements. Abstract Background: Alzheimer’s disease (AD) is a multifactorial neurodegenerative disorder in which age, genetics, vascular disease, metabolic dysfunction, hearing loss, physical inactivity, depression, social isolation and other modifiable factors contribute to risk. The prevention landscape has changed substantially since this article was first published in 2022. Objective: To update the evidence concerning practical strategies for reducing dementia risk, with particular attention to multidomain lifestyle interventions, nutritional adequacy, dietary supplements, blood-based biomarkers and emerging metabolic therapies. Metho...